Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Ruyi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Xanthones, Prodrugs, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Jiangsu Funding Program for Excellent Postdoctoral Talent, China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Poor in vivo characteristics of gambogic acid (GA) and difficulties in industrial manufacturing of its nanocarriers have hindered its clinical translation. Therefore, a reproducible nano‐drug delivery system must be developed to realize simpler manufacture and address inherent defects of GA, such as short circulation and severe side effects, in order to facilitate its clinical application. Herein, a drug self‐assembled nanoparticles (NPs) consisting of a hydrophobic prodrug based on GA and oleyl alcohol (OA), as well as vitamin E‐polyethylene glycol succinate (TPGS) as a shield to improve the stability of the NPs is reported. The preparation method is simple enough to stably facilitate large‐scale manufacturing. The self‐assembled NPs exhibit a remarkably high drug‐loading capacity, and their prolonged circulation enables the NPs to demonstrate superior antitumor efficacy in both cellular and animal models. The flexible hydrophobic long chain wraps GA groups, which mitigates vascular irritation and reduces hemolysis rates. Consequently, the prodrug nano‐system addresses GA‐related concerns regarding stability, efficacy, and safety, offering a simple, stable, and secure nano‐platform for similar candidate drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China.
- Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China.
- State Drug Administration-Key laboratory of Quality control of Chinese Medicinal Materials and Decoction Pieces, Gansu Institute for Drug Control, Lanzhou, 730070, China.
- Nanjing Medical University, Nanjing, 211198, China.
- Zhejiang Center for Safety Study of Drug Substances, Industrial Technology Innovation Platform, Hangzhou, 310018, China.
ORCID-Profile: Wei Qu
Förderung
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, R., Xiao, Y., Zhang, Z., Huang, X., Zhu, W., Ma, X., Feng, F., Liu, W., Han, L., & Qu, W. (2024). Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401950
Vancouver
Wang R, Xiao Y, Zhang Z, Huang X, Zhu W, Ma X, et al. Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401950
BibTeX
@article{Wang2024,
author = {Wang, Ruyi and Xiao, Yuxiao and Zhang, Zhongtao and Huang, Xiaoxian and Zhu, Wanfang and Ma, Xiao and Feng, Feng and Liu, Wenyuan and Han, Lingfei and Qu, Wei},
title = {Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401950}
}
EUVIMED